InvestorsHub Logo
Post# of 252341
Next 10
Followers 833
Posts 119913
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 22019

Friday, 02/03/2006 7:47:19 AM

Friday, February 03, 2006 7:47:19 AM

Post# of 252341
RHEO
I’ve said in manifold posts here over
the past two years that I thought
RHEO’s treatment for dry AMD was
a hoax. Based on the data released
today, it appears that the procedure
may in fact be a hoax. There were
many red flags along the way for
anyone who cared to look for them.
p.s. Cramer recently pumped this stock
mercilessly.

http://biz.yahoo.com/bw/060203/20060203005252.html?.v=1

>>
OccuLogix Provides MIRA-1 Update

Friday February 3, 7:00 am ET

TORONTO--(BUSINESS WIRE)--Feb. 3, 2006--OccuLogix, Inc. (NASDAQ: RHEO ; TSX: RHE ) has completed a preliminary analysis of the data from MIRA-1, its recently completed pivotal (phase III) clinical trial using its RHEO(TM) System to treat the dry form of age-related macular degeneration ("Dry AMD").

MIRA-1 did not demonstrate a statistically significant difference in the mean change of Best Spectacle-Corrected Visual Acuity applying the Early Treatment Diabetic Retinopathy Scale ("ETDRS BCVA") between the treated and placebo groups at 12-months post-baseline. As expected, the treated group demonstrated a positive response. An anomalous response of the control group is the principal reason that the primary efficacy endpoint was not met. [Balderdash!]

There were subgroups that did demonstrate statistical significance in their mean change of ETDRS BCVA versus control. Further analysis of the study data is being undertaken. [Blah, blah, blah.]

There is a large patient population suffering from Dry AMD, with limited therapies available to treat this devastating disease. The Company is in the process of evaluating the implications of the MIRA-1 study data on its application to the U.S. Food and Drug Administration for approval to market its RHEO(TM) System in the United States. OccuLogix will provide further updates as they become available.

About OccuLogix, Inc.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'. Visit us on the internet at www.occulogix.com (corporate) and www.rheo.com (healthcare professionals, patients and caregivers).
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.